Background: Pembrolizumab is the first-line standard of care for advanced non–small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) ≥ 50%. Eastern Cooperative Oncology Group performance status (PS) 2 patients may receive pembrolizumab, despite the absence of sustaining evidence. Patients and methods: GOIRC-2018-01 is a multicentre, retrospective, observational study. PS 2 NSCLC patients with a PD-L1 TPS ≥50% receiving first-line pembrolizumab from June 2017 to December 2018 at 21 Italian institutions were included. Clinical-pathological characteristics were correlated with disease response and survival outcomes; adverse events were recorded. The primary objective was 6-months progression-free rate (6-months PFR). Results: One hundred fifty-three patients (median age 70 years) were enrolled. At a median follow-up of 18.2 months, median progression-free survival (PFS) and overall survival (OS) were 2.4 (95% confidence interval, 95% CI, 1.6–2.5) and 3.0 months (95% CI 2.4–3.5), respectively. 6-months PFR was 27% (95% CI 21–35%). Patients with a PS 2 determined by comorbidities (n = 41) had significantly better outcomes compared with disease burden-induced PS 2 (n = 112). Indeed, 6-months PFR was 49% versus 19%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 months, respectively. Additional potential prognostic factors (radiotherapy, antibiotics, steroids received before pembrolizumab) correlated with clinical outcomes. The determinant of PS 2 resulted the only factor independently impacting on both PFS and OS. No toxicity issues emerged. Conclusions: Outcomes of PS 2 NSCLC patients with PD-L1 TPS ≥50% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself.

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status / Facchinetti F.; Mazzaschi G.; Barbieri F.; Passiglia F.; Mazzoni F.; Berardi R.; Proto C.; Cecere F.L.; Pilotto S.; Scotti V.; Rossi S.; Del Conte A.; Vita E.; Bennati C.; Ardizzoni A.; Cerea G.; Migliorino M.R.; Sala E.; Camerini A.; Bearz A.; De Carlo E.; Zanelli F.; Guaitoli G.; Garassino M.C.; Ciccone L.P.; Sartori G.; Toschi L.; Dall'Olio F.G.; Landi L.; Pizzutilo E.G.; Bartoli G.; Baldessari C.; Novello S.; Bria E.; Cortinovis D.L.; Rossi G.; Rossi A.; Banna G.L.; Camisa R.; Di Maio M.; Tiseo M.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 130:(2020), pp. 155-167. [10.1016/j.ejca.2020.02.023]

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Ardizzoni A.;Guaitoli G.;Dall'Olio F. G.;
2020

Abstract

Background: Pembrolizumab is the first-line standard of care for advanced non–small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) ≥ 50%. Eastern Cooperative Oncology Group performance status (PS) 2 patients may receive pembrolizumab, despite the absence of sustaining evidence. Patients and methods: GOIRC-2018-01 is a multicentre, retrospective, observational study. PS 2 NSCLC patients with a PD-L1 TPS ≥50% receiving first-line pembrolizumab from June 2017 to December 2018 at 21 Italian institutions were included. Clinical-pathological characteristics were correlated with disease response and survival outcomes; adverse events were recorded. The primary objective was 6-months progression-free rate (6-months PFR). Results: One hundred fifty-three patients (median age 70 years) were enrolled. At a median follow-up of 18.2 months, median progression-free survival (PFS) and overall survival (OS) were 2.4 (95% confidence interval, 95% CI, 1.6–2.5) and 3.0 months (95% CI 2.4–3.5), respectively. 6-months PFR was 27% (95% CI 21–35%). Patients with a PS 2 determined by comorbidities (n = 41) had significantly better outcomes compared with disease burden-induced PS 2 (n = 112). Indeed, 6-months PFR was 49% versus 19%, median PFS 5.6 versus 1.8 months and OS 11.8 versus 2.8 months, respectively. Additional potential prognostic factors (radiotherapy, antibiotics, steroids received before pembrolizumab) correlated with clinical outcomes. The determinant of PS 2 resulted the only factor independently impacting on both PFS and OS. No toxicity issues emerged. Conclusions: Outcomes of PS 2 NSCLC patients with PD-L1 TPS ≥50% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself.
2020
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status / Facchinetti F.; Mazzaschi G.; Barbieri F.; Passiglia F.; Mazzoni F.; Berardi R.; Proto C.; Cecere F.L.; Pilotto S.; Scotti V.; Rossi S.; Del Conte A.; Vita E.; Bennati C.; Ardizzoni A.; Cerea G.; Migliorino M.R.; Sala E.; Camerini A.; Bearz A.; De Carlo E.; Zanelli F.; Guaitoli G.; Garassino M.C.; Ciccone L.P.; Sartori G.; Toschi L.; Dall'Olio F.G.; Landi L.; Pizzutilo E.G.; Bartoli G.; Baldessari C.; Novello S.; Bria E.; Cortinovis D.L.; Rossi G.; Rossi A.; Banna G.L.; Camisa R.; Di Maio M.; Tiseo M.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 130:(2020), pp. 155-167. [10.1016/j.ejca.2020.02.023]
Facchinetti F.; Mazzaschi G.; Barbieri F.; Passiglia F.; Mazzoni F.; Berardi R.; Proto C.; Cecere F.L.; Pilotto S.; Scotti V.; Rossi S.; Del Conte A.; Vita E.; Bennati C.; Ardizzoni A.; Cerea G.; Migliorino M.R.; Sala E.; Camerini A.; Bearz A.; De Carlo E.; Zanelli F.; Guaitoli G.; Garassino M.C.; Ciccone L.P.; Sartori G.; Toschi L.; Dall'Olio F.G.; Landi L.; Pizzutilo E.G.; Bartoli G.; Baldessari C.; Novello S.; Bria E.; Cortinovis D.L.; Rossi G.; Rossi A.; Banna G.L.; Camisa R.; Di Maio M.; Tiseo M.
File in questo prodotto:
File Dimensione Formato  
Facchinetti_2020.pdf

accesso riservato

Tipo: Versione (PDF) editoriale
Licenza: Licenza per accesso riservato
Dimensione 1.4 MB
Formato Adobe PDF
1.4 MB Adobe PDF   Visualizza/Apri   Contatta l'autore
ScienceDirect_files_14Dec2023_11-41-08.683.zip

accesso riservato

Tipo: File Supplementare
Licenza: Licenza per accesso riservato
Dimensione 145.22 kB
Formato Zip File
145.22 kB Zip File   Visualizza/Apri   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/780916
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 102
  • ???jsp.display-item.citation.isi??? 95
social impact